Ophir Shahaf, Business Development, eHealth Ventures, Nimrod Bin-Nun, CEO and founder, RespirAI, Assaf Gur, VP R&D and founder, RespirAI, Talor Sax, Managing Partner, eHealth Ventures (Credit: EHV)
RespirAI Medical, a leading digital health startup from Israel, is advancing its efforts in home-based monitoring for Chronic Obstructive Pulmonary Disease (COPD) patients through expanded clinical trials.
In collaboration with the Mayo Clinic, RespirAI is supporting an investigator-initiated clinical trial led by Dr. Megan Dulohery Scrodin. The study focuses on evaluating RespirAI’s AI-powered wearable platform for remote monitoring of COPD patients recovering from bronchoscopic lung volume reduction with the Zephyr Valve procedure.
The trial aims to determine the technology’s ability to detect early signs of COPD exacerbations and pneumothorax, helping to reduce hospital readmissions and improve patient outcomes. By leveraging AI-driven respiratory monitoring, RespirAI seeks to revolutionize COPD management and home-based care, offering a proactive approach to chronic disease monitoring.
Will you offer us a hand? Every gift, regardless of size, fuels our future.
Your critical contribution enables us to maintain our independence from shareholders or wealthy owners, allowing us to keep up reporting without bias. It means we can continue to make Jewish Business News available to everyone.
You can support us for as little as $1 via PayPal at [email protected].
Thank you.
Chronic Obstructive Pulmonary Disease (COPD) is a progressive lung disease that makes it difficult to breathe. It is a common condition that affects millions of people worldwide. The most common cause of COPD is smoking. Long-term exposure to air pollution, dust, fumes, and chemicals can also cause COPD. And, in rare cases, COPD can be caused by a genetic condition called alpha-1 antitrypsin deficiency.
“This coming trial is a major step toward revolutionizing COPD care,” said Nimrod Bin-Nun, Co-Founder & CEO of RespirAI. “By combining cutting-edge technology with world-renowned medical expertise, we aim to provide patients and healthcare providers with real-time insights that enhance recovery and disease management.”
Empowering patients with respiratory diseases, RespirAI Medical is developing a cutting-edge, AI-driven, wearable home monitoring platform. The patient data is automatically uploaded to the cloud, where advanced algorithms, leveraging artificial intelligence (AI) are capable of analyzing deviations from the patient’s clinical baselines. The data analysis results are shared with the care team and the patient’s family when notifications are triggered, sensing changes in the patient’s health.
Dedicated to enhancing the well-being of individuals with chronic conditions, especially in pulmonology, RespirAI’s technology provides patients with the ability to monitor their health in real time, leading to earlier detection of worsening symptoms and improved control over their disease. This platform delivers numerous benefits, fostering better medication adherence, reducing the need for frequent clinic visits, and contributing to healthcare cost savings for patients, providers, and families. RespirAI is backed by eHealth Ventures, a key investor focused on early-stage digital health advancements.
